A detailed history of Charles Schwab Investment Management Inc transactions in Maxcyte, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 299,673 shares of MXCT stock, worth $1.31 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
299,673
Previous 298,912 0.25%
Holding current value
$1.31 Million
Previous $1.17 Million 0.51%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$3.68 - $5.06 $2,800 - $3,850
761 Added 0.25%
299,673 $1.17 Million
Q2 2024

Aug 12, 2024

BUY
$3.63 - $5.0 $203,352 - $280,100
56,020 Added 23.06%
298,912 $1.17 Million
Q1 2024

May 08, 2024

SELL
$3.94 - $5.38 $3,352 - $4,578
-851 Reduced 0.35%
242,892 $1.02 Million
Q4 2023

Feb 06, 2024

BUY
$2.6 - $5.24 $13,704 - $27,620
5,271 Added 2.21%
243,743 $1.15 Million
Q2 2023

Aug 09, 2023

SELL
$3.69 - $5.35 $697 - $1,011
-189 Reduced 0.08%
238,472 $1.09 Million
Q1 2023

May 11, 2023

BUY
$4.03 - $5.89 $22,229 - $32,489
5,516 Added 2.37%
238,661 $1.18 Million
Q4 2022

Feb 13, 2023

BUY
$4.92 - $7.4 $15,625 - $23,502
3,176 Added 1.38%
233,145 $1.27 Million
Q3 2022

Nov 14, 2022

BUY
$4.52 - $6.51 $175,362 - $252,568
38,797 Added 20.29%
229,969 $1.5 Million
Q2 2022

Aug 15, 2022

SELL
$3.59 - $6.81 $113,792 - $215,856
-31,697 Reduced 14.22%
191,172 $905,000
Q1 2022

May 13, 2022

BUY
$5.26 - $10.84 $79,147 - $163,109
15,047 Added 7.24%
222,869 $1.56 Million
Q4 2021

Feb 11, 2022

BUY
$8.87 - $12.94 $1.54 Million - $2.24 Million
173,485 Added 505.24%
207,822 $2.12 Million
Q3 2021

Nov 16, 2021

BUY
$12.21 - $17.2 $419,254 - $590,596
34,337 New
34,337 $420,000

Others Institutions Holding MXCT

About MAXCYTE, INC.


  • Ticker MXCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 101,724,000
  • Market Cap $446M
  • Description
  • MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...
More about MXCT
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.